免疫检查点抑制剂治疗癌症挽救性化疗的疗效和安全性

Pub Date : 2019-05-09 DOI:10.2217/lmt-2019-0001

M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh

{"title":"免疫检查点抑制剂治疗癌症挽救性化疗的疗效和安全性","authors":"M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh","doi":"10.2217/lmt-2019-0001","DOIUrl":null,"url":null,"abstract":"Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0001","citationCount":"14","resultStr":"{\"title\":\"Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer\",\"authors\":\"M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh\",\"doi\":\"10.2217/lmt-2019-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2019-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/lmt-2019-0001\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2019-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2019-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

摘要

目的：评估免疫检查点抑制剂（ICI）与挽救性化疗疗效的关系，以及挽救性化疗的安全性。患者和方法：对18例晚期NSCLC患者进行回顾性分析。我们评估了挽救性化疗的总有效率和不良事件。结果：对挽救性化疗的总有效率为33.3%，ICI应答者明显高于无应答者（分别为66.7%和16.7%，p=0.03）。挽救性化疗不良事件发生率为55.6%。结论：挽救性化疗疗效与ICI前相似。此外，挽救性化疗的安全性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助